Skip to main content
Clinical Trials/NCT02329353
NCT02329353
Completed
Phase 3

Clinical And Microbiological Analysis Of Orally Administered Lactobacillus Probiotic Lozenges In Chronic Periodontitis Patients Among Smokers And Non-smokers And Its Correlation With Clinical Parameters - A Clinico-Microbiological Study

Next Gen Pharma India Pvt. Ltd.1 site in 1 country60 target enrollmentFebruary 2015

Overview

Phase
Phase 3
Intervention
Lactobacillus brevis CD2 Lozenges
Conditions
Chronic Periodontitis
Sponsor
Next Gen Pharma India Pvt. Ltd.
Enrollment
60
Locations
1
Primary Endpoint
Improvement in Clinical Periodontal Indices
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Periodontitis is one of the most common chronic inflammatory disease with the etiology of bacterial plaque and is associated with a number of putative bacterial species. The periodontal destruction is substantially mediated by the host, driven by the bacterial challenge. The presence of pathogenic bacteria with the absence of so-called "beneficial bacteria" and the susceptibility of the host are the main aetiological factors of periodontal diseases.

Registry
clinicaltrials.gov
Start Date
February 2015
End Date
December 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Next Gen Pharma India Pvt. Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients free from any systemic illness
  • Previously untreated moderate to severe generalised chronic periodontitis.
  • Patients free from adverse reactions to lactose or fermented milk products
  • Patient unwilling to quit smoking and smokers over the past one year ( Smoker arm).

Exclusion Criteria

  • Previous history of antibiotic usage over past 6 months
  • Patients who are eligible for antibiotic usage during the treatment course
  • Patients who are pregnant, lactating, alcoholic or who had undergone any surgical or nonsurgical therapy within 6 months.
  • Acute oral lesions or necrotising ulcerative periodontitis

Arms & Interventions

Smoker group

30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks

Intervention: Lactobacillus brevis CD2 Lozenges

Non-smoker

30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks

Intervention: Lactobacillus brevis CD2 Lozenges

Outcomes

Primary Outcomes

Improvement in Clinical Periodontal Indices

Time Frame: 8 weeks

Improvement in clinical periodontal indices, namely, Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD)

Secondary Outcomes

  • Change in microbiological indices(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials